BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 35481923)

  • 1. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma.
    Price G; Bouras A; Hambardzumyan D; Hadjipanayis CG
    EBioMedicine; 2021 Jul; 69():103453. PubMed ID: 34157482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T cell therapies for diffuse midline glioma.
    Thomas BC; Staudt DE; Douglas AM; Monje M; Vitanza NA; Dun MD
    Trends Cancer; 2023 Oct; 9(10):791-804. PubMed ID: 37541803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy approaches for the treatment of diffuse midline gliomas.
    Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
    Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
    de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
    Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
    Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
    Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
    Majzner RG; Ramakrishna S; Yeom KW; Patel S; Chinnasamy H; Schultz LM; Richards RM; Jiang L; Barsan V; Mancusi R; Geraghty AC; Good Z; Mochizuki AY; Gillespie SM; Toland AMS; Mahdi J; Reschke A; Nie EH; Chau IJ; Rotiroti MC; Mount CW; Baggott C; Mavroukakis S; Egeler E; Moon J; Erickson C; Green S; Kunicki M; Fujimoto M; Ehlinger Z; Reynolds W; Kurra S; Warren KE; Prabhu S; Vogel H; Rasmussen L; Cornell TT; Partap S; Fisher PG; Campen CJ; Filbin MG; Grant G; Sahaf B; Davis KL; Feldman SA; Mackall CL; Monje M
    Nature; 2022 Mar; 603(7903):934-941. PubMed ID: 35130560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of socioeconomic status on clinical outcomes of diffuse midline glioma and diffuse intrinsic pontine glioma.
    Lee JH; Holste KG; Bah MG; Franson AT; Garton HJL; Maher CO; Muraszko KM
    J Neurosurg Pediatr; 2024 Jun; 33(6):507-515. PubMed ID: 38489807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.
    Schuelke MR; Wongthida P; Thompson J; Kottke T; Driscoll CB; Huff AL; Shim KG; Coffey M; Pulido J; Evgin L; Vile RG
    J Immunother Cancer; 2019 Jul; 7(1):188. PubMed ID: 31315671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse midline glioma: review of epigenetics.
    Cooney TM; Lubanszky E; Prasad R; Hawkins C; Mueller S
    J Neurooncol; 2020 Oct; 150(1):27-34. PubMed ID: 32804378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
    Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
    Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
    Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
    Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.
    Ausejo-Mauleon I; Labiano S; de la Nava D; Laspidea V; Zalacain M; Marrodán L; García-Moure M; González-Huarriz M; Hervás-Corpión I; Dhandapani L; Vicent S; Collantes M; Peñuelas I; Becher OJ; Filbin MG; Jiang L; Labelle J; de Biagi-Junior CAO; Nazarian J; Laternser S; Phoenix TN; van der Lugt J; Kranendonk M; Hoogendijk R; Mueller S; De Andrea C; Anderson AC; Guruceaga E; Koschmann C; Yadav VN; Gállego Pérez-Larraya J; Patiño-García A; Pastor F; Alonso MM
    Cancer Cell; 2023 Nov; 41(11):1911-1926.e8. PubMed ID: 37802053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine Glioma.
    Park J; Chung C
    Brain Tumor Res Treat; 2023 Apr; 11(2):86-93. PubMed ID: 37151150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
    Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
    Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics.
    Hoffman LM; DeWire M; Ryall S; Buczkowicz P; Leach J; Miles L; Ramani A; Brudno M; Kumar SS; Drissi R; Dexheimer P; Salloum R; Chow L; Hummel T; Stevenson C; Lu QR; Jones B; Witte D; Aronow B; Hawkins CE; Fouladi M
    Acta Neuropathol Commun; 2016 Jan; 4():1. PubMed ID: 26727948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
    Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
    J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
    Wang SS; Davenport AJ; Iliopoulos M; Hughes-Parry HE; Watson KA; Arcucci V; Mulazzani M; Eisenstat DD; Hansford JR; Cross RS; Jenkins MR
    Neurooncol Adv; 2023; 5(1):vdad024. PubMed ID: 37152812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.